The most common causes of chronic cough include gastroesophageal reflux disease (GERD), asthma, and postnasal drip (also known as upper airway cough syndrome), said Sean Duffy, MD, an associate ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores assessing cough severity and cough-related quality of life at day 28 from ...

Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two ...

Trevi is also conducting the phase IIb CORAL study, which is evaluating the drug in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Data from this study is expected in the first ...

GSK expects to launch its RCC drug commercially in 2026. Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two complete response ...